Evidence map›Paper›PMID 38668042›Full record

ArticleCurrent oncology (Toronto, Ont.)2024

Demographic Analysis of Cancer Research Priorities and Treatment Correlations.

Denis Horgan, Marc Van den Bulcke, Umberto Malapelle, Nicola Normanno, Ettore D Capoluongo, Arsela Prelaj, Carmelo Rizzari, Aliki Stathopoulou, Jaya Singh, Marta Kozaric and 14 more

Abstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Denis HorganEuropean Alliance for Personalised Medicine, 1040 Brussels, Belgium.ORCID 0000-0003-4392-4505
Marc Van den BulckeBelgian Cancer Centre, Sciensano, 1050 Brussels, Belgium.
Umberto MalapelleDepartment of Public Health, University Federico II of Naples, 80138 Naples, Italy.ORCID 0000-0003-3211-9957
Nicola NormannoIstituto Nazionale Tumori "Fondazione G. Pascale"-IRCCS, 80131 Naples, Italy.ORCID 0000-0002-7158-2605
Ettore D CapoluongoDepartment of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, 80138 Naples, Italy.
Arsela PrelajDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.ORCID 0000-0002-3863-088X
Carmelo RizzariUnità di Ematologia Pediatrica, Fondazione MBBM, Università di Milano-Bicocca, 20126 Monza, Italy.ORCID 0000-0002-4828-3893
Aliki StathopoulouEuropean Cancer Patient Coalition, 1000 Brussels, Belgium.
Jaya SinghEuropean Alliance for Personalised Medicine, 1040 Brussels, Belgium.
Marta KozaricEuropean Alliance for Personalised Medicine, 1040 Brussels, Belgium.
France DubeAstra Zeneca, Concord Pike, Wilmington, DE 19803, USA.
Manuel OttavianoDepartamento de Tecnología Fotónica y Bioingeniería, Universidad Politècnica de Madrid, 28040 Madrid, Spain.
Stefania BocciaSection of Hygiene, Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, 20123 Rome, Italy.ORCID 0000-0002-1864-749X
Gabriella PravettoniDepartment of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.
Ivana CattaneoNovartis Farma SpA, 21042 Origgio, Italy.
Núria MalatsGenetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.ORCID 0000-0003-2538-3784
Reinhard BuettnerLung Cancer Group Cologne, Institute of Pathology, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, 50937 Cologne, Germany.ORCID 0000-0001-8806-4786
Karim LekadirArtificial Intelligence in Medicine Lab (BCN-AIM), Universitat de Barcelona, 08007 Barcelona, Spain.
Francesco de LorenzoEuropean Cancer Patient Coalition, 1000 Brussels, Belgium.
Catherine Alix-PanabieresLaboratory of Rare Human Circulating Cells, University Medical Center of Montpellier, 34093 Montpellier, France.ORCID 0000-0002-6401-2903
Sara BadrehCancer Childhood International, 1200 Vienna, Austria.
Eric SolaryINSERM U1287, Gustave Roussy Cancer Campus, 94805 Paris, France.ORCID 0000-0002-8629-1341
Ruggero De MariaInstitute of General Pathology, Catholic University of the Sacred Heart, 20123 Rome, Italy.
Paul HofmanIHU RespirERA, FHU OncoAge, Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Université Côte d'Azur, 06000 Nice, France.ORCID 0000-0003-0431-9353

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Understanding the diversity in cancer research priorities and the correlations among different treatment modalities is essential to address the evolving landscape of oncology. This study, conducted in collaboration with the European Cancer Patient Coalition (ECPC) and Childhood Cancer International-Europe (CCI-E) as part of the "UNCAN.eu" initiative, analyzed data from a comprehensive survey to explore the complex interplay of demographics, time since cancer diagnosis, and types of treatments received. Demographic analysis revealed intriguing trends, highlighting the importance of tailoring cancer research efforts to specific age groups and genders. Individuals aged 45-69 exhibited highly aligned research priorities, emphasizing the need to address the unique concerns of middle-aged and older populations. In contrast, patients over 70 years demonstrated a divergence in research priorities, underscoring the importance of recognising the distinct needs of older individuals in cancer research. The analysis of correlations among different types of cancer treatments underscored the multidisciplinary approach to cancer care, with surgery, radiotherapy, chemotherapy, precision therapy, and biological therapies playing integral roles. These findings support the need for personalized and combined treatment strategies to achieve optimal outcomes. In conclusion, this study provides valuable insights into the complexity of cancer research priorities and treatment correlations in a European context. It emphasizes the importance of a multifaceted, patient-centred approach to cancer research and treatment, highlighting the need for ongoing support, adaptation, and collaboration to address the ever-changing landscape of oncology.

Indexed as

NeoplasmsAdultAgedBiomedical ResearchDemographyEuropeFemaleHumansMaleMiddle AgedResearchcancerdemographicsoncologypatientspersonalized medicinepolicyprioritiesresearch

Identifiers

PMID38668042
PMCPMC11048756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.